Detection of minimal residual disease by next generation sequencing in AL amyloidosis

Blood Cancer J. 2021 Jun 21;11(6):117. doi: 10.1038/s41408-021-00511-6.

Shayna Sarosiek^{1

2}, Cindy Varga^{3

4}, Allison Jacob⁵, Maria Teresa Fulciniti⁶, Nikhil Munshi⁶, Vaishali Sanchorawala^{7

8}

¹ Section of Hematology & Medical Oncology, Boston Medical Center, Boston, MA, USA.
² Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.
³ The John C Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA, USA.
⁴ Division of Hematology-Oncology, Tufts Medical Center, Boston, MA, USA.
⁵ Adaptive Biotechnologies, Seattle, WA, USA.
⁶ Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
⁷ Section of Hematology & Medical Oncology, Boston Medical Center, Boston, MA, USA. Vaishali.Sanchorawala@bmc.org.
⁸ Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA. Vaishali.Sanchorawala@bmc.org.

No abstract available

Publication types